Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04768985 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT04768985: Completed Phase 1 study, sponsored by AstraZeneca.
NCT04768985 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04768985, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.
Primary Outcome
To compare the AUCinf of acalabrutinib capsule with the tablet.
Interventions
- DRUG Treatment A: Acalabrutinib tablet
- DRUG Treatment B: Acalabrutinib capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2021-05-10 |
| Phase | Phase 1 |
What the finished NCT04768985 record still lists
NCT04768985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which Treatment A: Acalabrutinib tablet is the first listed.
NCT04768985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04768985 about?
NCT04768985 is a clinical study titled "Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule". This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment ...
What is the current status of trial NCT04768985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2021-02-25. Estimated completion is 2021-05-10.
What interventions are being tested in trial NCT04768985?
The interventions under investigation include: Treatment A: Acalabrutinib tablet (DRUG), Treatment B: Acalabrutinib capsule (DRUG).
Who is sponsoring clinical trial NCT04768985?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04768985's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI